Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Table 2 Summary table on costs and utilities for HPV-related disease

HPV-related disease	Cost (€)		References	Utility		References
HPV-related disease	Females	Males	References	Males	Females	References
CIN 1	452.0		[22]		0.8396	[22]
CIN 2	1485.0		[22]		0.7967	[22]
CIN 3, CIS	1971.8		[22]		0.8396	[22] (assumption on CIS)
Cervical cancer, local disease	20,652.7		[22]		0.54375	[22]
Cervical cancer, regional disease	35,930.4		[22]		0.5701	[22]
Cervical cancer, distant disease	34,574.7		[22]		0.4517	[22]
VaIN 2	3237.0		[22]		0.9793	[22]
VaIN 3, CIS	3237.0		[22]		0.9793	[22]
Vaginal cancer, local disease	7703.2		[22]		0.54375	[22]
Vaginal cancer, regional disease	19,835.9		[22]		0.5701	[22]
Vaginal cancer, distant disease	29,646.9		[22]		0.4517	[22]
Vulvar cancer, local disease	7183.7		[22]		0.54375	[22]
Vulvar cancer, regional disease	16,032.6		[22]		0.5701	[22]
Vulvar cancer, distant disease	20,365.4		[22]		0.4517	[22]
Penile cancer, local disease		10,497.6	[15]	0.7922		[22]
Penile cancer, regional disease		10,497.6	[15]	0.7922		[22]
Penile cancer, distant disease		10,497.6	[15]	0.7922		[22]
Anal cancer, local disease	9812.4	9812.4	[22]	0.653	0.69615	[22]
Anal cancer, regional disease	18,480.4	18,480.4	[22]	0.4175	0.5172	[22]
Anal cancer, distant disease	11,993.6	11,993.6	[22]	0.1998	0.2244	[22]
Head & Neck cancer, local disease	10,081.7	10,081.7	[22]	0.8171	0.7413	[22]
Head & Neck cancer, regional disease	28,572.1	28,572.1	[22]	0.5601	0.551	[22]
Head & Neck cancer, distant disease	28,572.1	28,572.1	[22]	0.5601	0.551	[22]
Genital warts	700.3	495.8	[15]	0.6961	0.7761	[22]
Recurrent respiratory papillomatosis	195,814.9	195,814.9	[15]	0.795698925	0.795698925	[53]

ISSN: 1478-7547